Search

Additional file 3. EpiGRAPH Hub Concept sheet.

Additional file 2. Web survey. Survey answered by postgraduate students, in-country experts, and other global health professionals.

Additional file 1. COVID-19 Epidemiological Report. Mauritius. Example In-depth epidemiological report. One out of 45 developed by the GRAPH network.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 30 September 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and from observational studies. This report particularly focuses on the latest data on vaccine effectiveness, updates on the Janssen COVID-19 vaccine, booster doses, and new data on the safety and immunogenicity of the Sinopharm and Pfizer and BioNtech vaccine in children.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 02 November 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and from observational studies. This report particularly focuses on the latest data on vaccine effectiveness, mRNA COVID-19 vaccine for children, duration of protection and waning immunity, and booster doses.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of August 16, 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and, in some cases, from observational studies. This report particularly focuses on heterologous vaccination schedules (e.g., mixing ChAdOx1 and mRNA vaccines), Sinopharm/ BBIBP-CorV and Sinovac/ CoronaVac's inactivated vaccines, and provides the latest updates and information on children and adolescent vaccinations.

This report addresses the most relevant data on COVID-19 vaccines literature as of 27 August, 2021. The current report addresses vaccine effectiveness against SARS-CoV-2 infection, focusing in particular, on vaccine effectiveness against variants, vaccine duration of protection, virus transmissibility and shedding post vaccination, the administration of booster doses, and the importance of children and adolescent's timely vaccination. Lastly, the report highlights the latest updates regarding ‘new' SARS-CoV-2 vaccines.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 11 November 2021. Bharat Biotech's new vaccine COVAXIN/ BBV152 received WHO EUL authorisation on 3 November 2021 leading to seven vaccines being now authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), Sinovac/CoronaVac (China), and COVAXIN/BBV152 (Bharat Biotech, India)]. This report provides a condensed summary concerning vaccine efficacy or effectiveness, safety, protection against variants, and further important information for each vaccine in the form of a synoptic table. The data in this synoptic table were extracted from phase III clinical trials and observational studies. This report focuses on the latest data on vaccine effectiveness, breakthrough infections, booster doses, and vaccinations in children.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 13 September 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. Additionally, information regarding the yet-to-be-approved1 Novavax vaccine NVX-COV2373 was added to the table, upon request of the Federal Office of Public Health (FOPH). Novavax is currently awaiting FDA and WHO EUL approval after assessing safety and immunogenicity in Phase 1/2 clinical trials. NVX-CoV2373 is currently in two pivotal Phase 3 studies to evaluate vaccine efficacy, safety, and immunogenicity2. The information and data in this synoptic table was extracted from phase III clinical trials and from observational studies. This report particularly focuses on vaccine efficacy and effectiveness, including variants, booster doses, and safety concerns such as myocarditis cases reported after COVID-19 vaccination in adults and children.

This report addresses the most relevant data on COVID-19 vaccines literature as of 02 November 2021. The current report addresses the latest data on vaccine effectiveness and its duration of protection, the vaccine-induced humoral, cellular, and neutralizing response over time, the effects of vaccination on transmissibility of SARS-CoV-2, vaccine booster doses, reported cases of myocarditis, the Pfizer and BioNTech vaccine in children, and the concomitant administration of the COVID-19 and Flu vaccines. To conclude, the report highlights the latest SARS-CoV-2 vaccine development information on COVID-19 vaccine candidates.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 26 November 2021. Bharat Biotech's new vaccine COVAXIN/ BBV152 received WHO EUL authorisation on 3 November 2021 leading to seven vaccines being now authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), Sinovac/CoronaVac (China), and COVAXIN/BBV152 (Bharat Biotech, India)]. This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and observational studies. This report focuses on the latest data on vaccine effectiveness, vaccine induced immunity, breakthrough infections, and booster doses.

This report provides an in-depth review of the seven1 World Health Organization's (WHO) Emergency Use Listing (EUL) authorized vaccines: BNT162b2/ COMIRNATY (Pfizer-BioNTech, USA), Spikevax/ Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ ChAdOx1 nCoV-19/ AZD1222/ Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/ Ad26CoV2.S/ Johnson & Johnson (Janssen, USA), Sinopharm/ BBIBP-CorV (China), Sinovac/ CoronaVac (China), and COVAXIN/ BBV152 (Bharat Biotech, India)]. The current report summarises the latest data on COVID-19 vaccine-related literature as of 13 December 2021, and presents the information in the form of a synoptic table. This report covers vaccine effectiveness, protection against variants, transmissibility, breakthrough infections, booster doses, COVID-19 vaccines for children, and further important information for each vaccine. The latest changes and additions to the synoptic table are highlighted in yellow.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 15 October 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and from observational studies. This report particularly focuses on the latest data on vaccine effectiveness, duration of protection and waning immunity, booster doses, efficacy and safety of NVX-CoV2372, and myocarditis.

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 27 August, 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and from observational studies. This report particularly focuses on vaccine effectiveness and vaccine efficacy and effectiveness against variants.

This report addresses the most relevant data on COVID-19 vaccines literature as of 26 November 2021. The current report addresses the latest data on the new WHO EUL approved vaccine COVAXIN/BBV152, vaccine effectiveness its waning immunity and duration of protection, the vaccine-induced humoral, cellular, and neutralizing response of the Chinese inactivated vaccines, breakthrough infections, virus transmissibility, vaccine booster doses, COVID-19 vaccines in children, COVID-19 vaccine safety and myocarditis. To conclude, the report highlights the latest SARS-CoV-2 vaccine development information on COVID-19 vaccine candidates.